Is cancer really a 'local' cellular clonal disease?

Medical Hypotheses

Volumn 59, Issue 5, 2002, Pages 560-565

  Bronchud, M H ^a  

^a HOSPITAL GENERAL DE CATALUNYA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CARCINOGENESIS; CELL CLONE; CELL DEATH; GENE MUTATION; GENE TECHNOLOGY; HUMAN; HYPOTHESIS; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY; ADULT; AGED; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CANCER STEM CELL; CARCINOMA; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; CHILD; EXPERIMENTAL NEOPLASM; FAMILIAL CANCER; FEMALE; GENETICS; GENOMICS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM; ONCOGENE; PATHOLOGY; PRECANCER; PROTEOMICS;

ANTINEOPLASTIC AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CLONE CELLS; FEMALE; GENOMICS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC SYNDROMES, HEREDITARY; ONCOGENES; PRECANCEROUS CONDITIONS; PROTEOMICS; TUMOR STEM CELLS;

EID: 0036839478     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00240-2     Document Type: Article

References (46)

1. Leblond C. Classification of cell populations on the basis of their proliferative behavior. Natl Cancer Inst Monogr 1964; 14: 119-150.
2. Fialkow P. Clonal origin of human tumors. Biochim Biophys Acta 1976; 458: 283-321.
3. Cairns J. Cancer: Science and Society. San Francisco, CA: W.H. Freeman, 1978.
4. Collins R. D. Is clonality equivalent to malignancy: Specifically, is immunoglobulin gene rearrangement diagnostic of malignant lymphoma?. Hum Pathol 1997; 28: 757-759.
5. Birindelli S., Aiello A., Lavarino C. et al. Genetic markers in sporadic tumors. In: Bronchud et al., (eds). Principles of Molecular Oncology. Clifton, NJ: Humana Press, 2000: 45-93.
6. Fisher J. C., Hollomon J. H. A hypothesis for the origin of cancer foci. Cancer 1951; 4: 916-918.
7. Nordling C. O. A new theory on the cancer-inducing mechanism. Br J Cancer 1953; 7: 68-72.
8. Armitage P., Doll R. The age-distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954; 8: 1-12.
9. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
10. Fisher J. C. Multiple-mutation theory of carcinogenesis. Nature 1958; 181: 651-652.
11. Armitage P., Doll R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 1957; 11: 161-169.
12. Friedewald W. F., Rous P. The initiating and promoting elements in tumor production. J Exp Med 1944; 80: 101-126.
13. Baltimore D. Viruses, polymerases and cancer. Science 1976; 192: 632-636.
14. Temin H. M. The protovirus hypothesis: Speculations on the significance of RNA-directed DNA synthesis for normal development and for carcinogenesis. J Natl Cancer Inst 1971; 46: iii-viii.
15. Knudson A. G. Mutation and human cancer. Adv Cancer Res 1973; 17: 317-352.
16. Doll R. Nature and nurture: Possibilities for cancer control. Carcinogenesis (London) 1996; 17: 177-184.
17. Couch D. B. Carcinogenesis: Basic principles. Drug Chem Toxicol 1996; 19: 133-148.
18. Shields P. G., Harris C. C. Molecular epidemiology and the genetics of environmental cancer. J Am Med Assoc 1991; 266: 681-687.
19. Harris C. C. The Walter Hubert Lecture. Molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumor suppressor gene. Br J Cancer 1996; 73: 261-269.
20. Perera F. P. Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996; 88: 496-509.
21. Kinzler K. W., Vogelstein B. Gatekeepers and caretakers. Nature (London) 1997; 386: 761-763.
22. Loeb L. A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991; 51: 3075-3080.
23. Loeb L. A. Cancer cells exhibit a mutator phenotype. Adv Cancer Res 1998; 72: 25-56.
24. Ponder B. Genetic testing for cancer risk. Science (Washington, DC) 1997; 278: 1050-1054.
25. Kinzler K. W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
26. Bronchud M. H., Peters W. P. Selecting the right targets for cancer therapy. In: Bronchud K. et al., (eds). Principles of Molecular Oncology. Clifton, NJ: Humana Press, 2000: 3-27.
27. Banks R. E., Dunn M. J., Hochstrasser D. F. et al. Proteomics: New perspectives, new biomedical opportunities. Lancet 2000; 356: 1749-1756.
28. Frykberg E. R., Bland K. I. 'In situ' breast carcinoma. Adv Surg 1993; 26: 29-72.
29. Page D. L., Dupont W. D., Rogers L. W., Rados M. S. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (Philadelphia) 1985; 55: 2698-2708.
30. Day D. W., Morson B. C. The adenoma-carcinoma sequence. In: J. L. Bennington (ed). The Pathogenesis of Colorectal Cancer, vol. 10. Philadelphia: Saunders, 1978: 58-71, chapter 6,
31. Bostwick D. G. Prostatic intraepithelial neoplasia (PIN): Current concepts. J Cell Biochem 1992; 16H: 10-19.
32. Califano J., van der Riet P., Westra W. et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996; 56: 2488-2492.
33. Sidransky D., Mikkelsen T. et al. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature (London) 1992; 355: 846-847.
34. Sidransky D., Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes and growth factors. Urol Clin North Am 1992; 19: 629-639.
35. Slaughter D. P., Southwick H. W., Smejkal W. 'Field cancerization' in oral stratified squamous epithelium. Cancer (Philadelphia) 1953; 6: 963-968.
36. Knowles M. A. The genetics of transitional cell carcinoma: Progress and potential clinical applications. Br J Urol Int 1999; 84: 412-427.
37. Ahrendt S. A., Chow J. T., Xu L. H. et al. Molecular detection of tumor cells in bronchioalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91: 332-339.
38. Bedi G. C., Westra W. H., Gabrielson E. et al. Multiple head and neck tumors: Evidence for a common clonal origin. Cancer Res 1996; 56: 2484-2487.
39. Partridge M., Emilion G., Pateromichelakis S. et al. Field cancerisation of the oral cavity: Comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Oral Oncol 1997; 33: 332-337.
40. Van Oijen M. G. C., Slootweg P. J. Oral field cancerization: Carcinogen-induced independent events or micrometastatic deposits. Cancer Epidemiol Biomarkers Prev 2000; 9: 249-256.
41. Kelloff G. J., Sigman C. C., Johnson K. M. et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 127-137.
42. Miller A. B., Bartsch H., Boffetta P., Dragsted L., Vainio H. Biomarkers in cancer chemoprevention. IARC Sci Publ 2001; 154.
43. Moolgavkar S., Krewski D., Zeise L., Cardis E., Moller H. Quantitative estimation and prediction of human cancer risks. IARC Sci Publ 1999; 131.
44. Kersting M., Friedl C., Kraus A. et al. Differential frequencies of p16 (INK4a) promoter hypermethyiation, p53 mutation, and K-ras mutation in exfotiative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000; 18: 3221-3229.
45. Issa J. P. The epigenetics of colorectal cancer. Ann N Y Acad Sci 2000; 910: 140-153.
46. Konrad M., Ge Y., Naber J. et al. Leukemic clones are frequently present in neonatal blood samples of children with acute lymphoblastic leukemia. Am Assoc Cancer Res A 2001; 2196: 408.